Berenberg lowered the firm’s price target on AstraZeneca (AZN) to EUR 140 from EUR 150 and keeps a Buy rating on the shares. Within the space of a year, AstraZeneca’s share price has given up all of its gains following further disappointment in Dato-DXd lung cancer data and elevated investor fears regarding employee investigations in China, the analyst tells investors in a research note. However, the firm says the company’s pipeline prospects are largely unchanged and the China impact appears to be limited.

Don't Miss our Black Friday Offers:

• Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on AZN:

• Grail tests first patient for TROPION-Lung12 Phase 3 study

• Lunit announces collaboration with AstraZeneca to develop AI-powered tools

• AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC

• FDA Cellular, Tissue & Gene Therapies Advisory Committee holds virtual meeting

• Soros boosts stake in AstraZeneca, exits Apple position